At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 269 enrolled
Drug / intervention
DVS SRdrug
Likely dose
DVS SR 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating DVS SR for Major Depressive Disorder. Completed, enrolled 269 participants across 35 sites in 2 countries.
Detailed Summary
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesMexico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartFeb 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedJun 13, 2011
Enrollment StartFeb 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.1 years ago
Interventions
DVS SRdrug
Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.